Cejalvo, J., Jacob, W., Kanonnikoff, T., Felip, E., Mendivil, A., Garcia, M., . . . Cervantes, A. (2019). A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.
Citación estilo ChicagoCejalvo, JM, et al. A Phase Ib/II Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel As First-line Treatment in Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer. 2019.
Cita MLACejalvo, JM, et al. A Phase Ib/II Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel As First-line Treatment in Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer. 2019.